ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Clinical Applications of ctDNA in Breast Cancer Diagnosis and Manage…

University of Miami Sylvester Comprehensive Cancer Center

D. Tripathy

ESMO 2024 Summary: The Emerging Global Epidemic of Early-Onset Cance…

2024 ESMO Annual Meeting Insights Hub

S. Ogino

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

Visible vs. Invisible Cancers - The Genomics and Natural History

Laurence Klotz

Sequencing Cellular Therapy and Bispecific Antibodies in DLBCL

Megan Melody

ASCO® 2024 Precision Medicine Highlights: LAURA and CROWN Trials (NS…

2024 ASCO® Annual Meeting Insights Hub

V. Subbiah

Lymphoma Hot Topics in 2024: Focus on DLBCL and cHL

Yale Cancer Center

T. Sethi

Sequencing of Bispecifics With Other Therapies in DLBCL

UChicago Medicine

E. Budde

Cancer Genomics: Molecular Profile Interpretation 101

Total Health

L. Welch

The Relapsed and Refractory MM Patient: When Immune Approaches Are I…

Joseph Mikhael

Tafasitamab + Lenalidomide vs. CIT for Transplant-Ineligible R/R DLB…

Patrizia Mondello

Managing R/R LBCL Patients Treated With Pola-R-CHP in 1L and Are CAR…

University of Colorado Cancer Center

M. Kamdar

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Moffitt Cancer Center

J. Chavez

Clinical Implications of Tumor Agnostic Therapies

Shivaani Kummar

History of Cancer and Its Treatment: What Will It Take to Cure?

University of Colorado Cancer Center

C. Lieu

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

New Updates in Frontline DLBCL

Scripps Health

L. Nastoupil